CME Topics

Nephrology & Family Medicine

Sea Courses is pleased to invite you on a 5-night CME AWAY® Resort program in Nassau, Bahamas. Dr. Sheldon Tobe and Dr. Alan Bell have developed an educational program that will be highly interactive and of interest to family physicians, specialists, and allied health professionals.   Dr. Bell is an executive health physician at Cleveland Clinic Canada.  He is Assistant Professor in the Department of Family and Community Medicine at the University of Toronto and has been practicing family medicine for over 4 decades. In addition to his clinical work, he’s a founding member, immediate past vice president and board of directors of Thrombosis Canada. He has co-authored 5 national guidelines for the Canadian Cardiovascular Society, acting as co-chair on two.  Dr. Bell is also a co-author of the Canadian Hypertension Guidelines and past member of the Hypertension Canada board of directors. Dr. Bell has been nominated by the College of Family Physicians of Canada for Family Physician of the year and is a recipient of their Award of Excellence. Dr. Bell will discuss Dyslipidemia, Osteoporosis, Insomnia and Venous Thromboembolism.   Dr. Tobe is a Professor of Medicine at both the University of Toronto and the Northern Ontario School of Medicine, where he was the inaugural Heart and Stroke Foundation Chair of Aboriginal and Rural Health Research from 2013 to 2018. Dr. Tobe was chair of the Canadian Hypertension Education Program from 2008 to 2012 and on the board of directors of Hypertension Canada to 2018 and remains co-chair of the Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE). Dr. Tobe has had continuous peer reviewed funding for over 25 years, received many teaching awards and other career distinctions, and has published over 200 peer-reviewed articles and led and participated in peer reviewed and investigator initiated multicentered international research collaborations. For this program, Dr. Tobe will discuss Diabetes and Advanced Nephropathy, Diabetes and CVD, Hypertension and Vaccinations to Prevent Heart Disease and Stroke.   Dr. Bell and Dr. Tobe are looking forward to seeing you in the Bahamas.  

Dr. Bell-

• 2025 Dyslipidemia Update
  • Apply to practice the key updates to the Canadian Cardiovascular Society Dyslipidemia Guidelines for primary and secondary vascular prevention
  • Identify those patients who would benefit from additional therapy beyond statins to reduce CV risk
  • Utilize in practice advanced therapies for lipid reduction and reduced CV risk
• Osteoporosis: Essentials for Effective Practice
  • Cite the burden of osteoporosis and fragility fractures
  • Examine the consequences of fracture for patients, caregivers and the health system
  • Interpret clinical criteria to appropriately risk stratify patients for fragility fracture
  • Explore and act on imminent fracture risk
  • Appropriately treat patients with antiresorptive and anabolic therapies
• Pearls in Thrombosis 2 Venous Thromboembolism
  • Optimally diagnose and manage venous thromboembolic disorders (VTE) including deep vein thrombosis and pulmonary embolism
  • Determine the optimal duration of antithrombotic therapy in VTE for secondary prevention
• Evolution of Insomnia Management
  • Examine chronic insomnia as an independent disorder when co-morbidities are present including anxiety and depression
  • Evaluate insomnia treatments: Sleep, sleep stages, daytime functioning
  • Contrast dual orexin receptor antagonists (DORAs) from conventional therapies in the management of chronic insomnia

Dr. Tobe-

• C-CHANGE Case #1 "TOM": Management of Patients with Diabetes and Hypertension
  • Identify the Canadian blood pressure targets for patients with diabetes.
  • Formulate a treatment plan for patients with diabetes and hypertension using the C-CHANGE recommendations.
  • Assess the risks associated with diabetes in patients with hypertension and the evidence supporting the use of RAAS blockers; and the risks of RAAS blockers use in diabetic nephropathy
• C-CHANGE Case #6 :  CV Risk Reduction in Patients with DM
  • Describe the patient who should be treated with an SGLT2i GLP1-RA agonist and nsMRA for CVD protection
  • Explain the rationale for this treatment and the potential benefits
  • Describe the steps for initiating and monitoring therapy for patients with diabetes
• Renal Protection in Patients with DM and Advanced Nephropathy
  • Describe advanced diabetic nephropathy and its consequences
  • Explain the rationale for the management of advanced nephropathy and the potential benefits
  • Describe how advanced nephropathy might be prevented
• Vaccination to Prevent Heart Disease and Stroke, and Maybe Vascular Cognitive Impairment
  • Describe the evidence that vaccination against influenza, pneumonia, and herpes zoster in high-risk people  prevents heart disease and stroke
  • Describe the public health approach to raising awareness in health care providers and the public at risk.
  • Explain how to facilitate vaccinations for high-risk people seen in specialty and primary care clinics
  • Outline the data suggesting that vaccination may also be preventing vascular cognitive impairment